Hospira's Epogen Biosimilar Appears Poised For Quick Advisory Cmte. OK
US FDA will hold its first-ever half-day panel review for a biosimilar; Hopsira's epoetin, which references Amgen's Epogen, has no clinically meaningful differences despite clinical trial conduct issues and PK/PD uncertainty, agency concludes.
